Welcome to our dedicated page for Cabaletta Bio SEC filings (Ticker: CABA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cabaletta Bio, Inc. filings document regulatory disclosures for a Nasdaq-listed biotechnology issuer developing engineered T cell therapies for autoimmune diseases. Form 8-K reports cover operating and financial results, corporate presentations, material agreements, and clinical or regulatory updates involving rese-cel and the RESET clinical development program.
Proxy materials describe annual meeting voting matters and governance for holders of Cabaletta Bio common stock. The filing record also identifies the company’s registered common stock, capital-structure disclosures, risk-oriented forward-looking statements, and formal material-event reporting tied to its cell-therapy development and manufacturing strategy.
Cabaletta Bio received an amended Schedule 13G showing that T. Rowe Price Investment Management, Inc. beneficially owns 9,858,257 shares of its common stock, representing 10.2% of the class. The firm reports sole voting power over 9,804,684 shares and sole dispositive power over 9,858,257 shares.
The filing notes that these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Cabaletta Bio. T. Rowe Price Small-Cap Value Fund holds 5,169,039 shares, representing 5.4% of the common stock class reported.
Cabaletta Bio Chief Medical Officer David J. Chang reported buying 8,800 shares of Cabaletta Bio common stock on January 21, 2026. The purchase was made in an open-market transaction coded “P” at a price of $2.26 per share. After this transaction, he directly owns 8,800 common shares of the company.
Cabaletta Bio, Inc. officer Gwendolyn Binder, President, Science & Tech., reported an open-market purchase of company stock. On January 21, 2026, she bought 11,312 shares of Cabaletta Bio common stock at a price of $2.1891 per share.
Following this transaction, Binder directly holds a total of 31,312 shares of Cabaletta Bio common stock, according to the filing.
Cabaletta Bio director reports indirect stock purchase
A reporting person associated with Cabaletta Bio, Inc. bought 22,725 shares of the company’s common stock on January 21, 2026 at a price of $2.2144 per share. Following this transaction, the reporting person is shown as beneficially owning 22,725 common shares, all held indirectly.
The shares are held through an entity named Shawn Tomasello Consulting LLC, rather than in the individual’s direct name. The filing is signed by an attorney-in-fact, indicating the use of an authorized representative to submit the Form 4.
Cabaletta Bio, Inc. insider trade: Chief Commercial Officer Steve Gavel reported purchasing 22,170 shares of Cabaletta Bio common stock on January 21, 2026. The Form 4 shows this as an open-market buy coded "P" at a weighted average price of $2.265 per share.
According to the filing, the shares were acquired in multiple trades at prices ranging from $2.26 to $2.27 per share, and Gavel beneficially owns 22,170 common shares following this transaction, held directly. The insider also notes a commitment to make detailed trade price information available to the company, its security holders, or the SEC staff upon request.
Cabaletta Bio, Inc. director Catherine Bollard reported a purchase of 4,405 shares of the company’s common stock. The transaction took place on 01/21/2026 at a price of $2.2661 per share, according to a Form 4 insider trading report.
Following this open-market purchase, Bollard’s reported beneficial ownership increased to 5,405 shares, held directly. The filing indicates the transaction code "P," which denotes a purchase of non-derivative securities.
Cabaletta Bio, Inc. President & CEO Steven Nichtberger reported buying 45,000 shares of the company’s common stock on January 21, 2026 at a weighted average price of $2.2395 per share. The filing notes these shares were purchased in multiple trades at prices ranging from $2.1985 to $2.26. Following this direct purchase, he beneficially owned 1,031,483 shares held directly.
The Form 4 also shows an additional 363,000 shares reported as indirectly held by the 2017 Nichtberger Family Trust, for which he disclaims beneficial ownership. The price detail and range are available on request from the issuer or the SEC staff, as stated in the footnote.
Cabaletta Bio director Simon Mark reported buying additional company stock. On January 21, 2026, he purchased 11,061 shares of Cabaletta Bio common stock at a weighted average price of $2.2838 per share. The filing notes that these shares were bought in multiple trades at prices ranging from $2.245 to $2.32 and that detailed trade information is available upon request.
After this transaction, Mark beneficially owned 147,205 shares of Cabaletta Bio common stock directly. The filing also reports 7,000 shares held indirectly by his spouse, reflecting additional beneficial ownership connected to him.
Cabaletta Bio, Inc. General Counsel Gerard Michael reported a purchase of 6,600 shares of common stock. The Form 4 shows that on 01/21/2026, he bought 6,600 Cabaletta Bio common shares at a weighted average price of $2.2696 per share, coded as a purchase (P). After this transaction, he beneficially owned 6,600 common shares held directly.
The filing notes that the reported price is a weighted average, with individual purchase prices ranging from $2.269 to $2.2699 per share, and that detailed price breakdowns are available from the company or the reporting person upon request.
Cabaletta Bio filed an 8-K outlining its 2026 strategic priorities for rese-cel, its investigational CD19 CAR T therapy for autoimmune diseases. The company has initiated a dermatomyositis and antisynthetase myositis registrational cohort expected to evaluate 17 patients, targeting a Biologics License Application submission for rese-cel in myositis next year. Cabaletta has aligned with the FDA on new registrational cohort designs in systemic lupus erythematosus and lupus nephritis and received a Regenerative Medicine Advanced Therapy designation for systemic sclerosis, with further regulatory alignment updates planned in 1H26 and mid-2026. The company also obtained IND clearance to use Cellares’ automated Cell Shuttle platform for rese-cel manufacturing and expects multiple Phase 1/2 data readouts across RESET trials in 1H26.
Cabaletta Bio filed an 8-K outlining its 2026 strategic priorities for rese-cel, its investigational CD19 CAR T therapy for autoimmune diseases. The company has initiated a dermatomyositis and antisynthetase myositis registrational cohort expected to evaluate 17 patients, targeting a Biologics License Application submission for rese-cel in myositis next year. Cabaletta has aligned with the FDA on new registrational cohort designs in systemic lupus erythematosus and lupus nephritis and received a Regenerative Medicine Advanced Therapy designation for systemic sclerosis, with further regulatory alignment updates planned in 1H26 and mid-2026. The company also obtained IND clearance to use Cellares’ automated Cell Shuttle platform for rese-cel manufacturing and expects multiple Phase 1/2 data readouts across RESET trials in 1H26.